Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)

NCT06968741 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-05-19
Last updated
2026-10-23

Condition(s) studied

Stress Urinary Incontinence (SUI)

Investigational drug(s) / intervention(s)

Artificial Urinary Sphincter (AUS)

Artificial Urinary Sphincter (AUS): AUS implant

Study summary

Prospective, multicenter, single-arm study

Eligibility

Sex
MALE
Min age
22 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Male subjects aged ≥ 22 years old * Able to read, comprehend and willing to sign an informed consent form * Primary diagnosis of stress urinary incontinence for at least 6 months, as assessed by the investigator * Appropriate surgical candidate with no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator Key Exclusion Criteria: * Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study (for urinary incontinence) in the past 3 months prior to informed consent * Poor candidate for surgical procedures and/or anesthesia, as determined by investigator * Currently implanted with an Active Implantable Medical Device (AIMD) * Symptoms or diagnosis of urge incontinence or mixed incontinence (MI) with a predominant urgency component, as assessed by the investigator

Primary outcome measure(s)

  • Responder rate at 26 weeks post-activation — 26 weeks
    Proportion of subjects who report greater than or equal to 50% reduction in the 24 hour Pad Weight Test (PWT) at 26 weeks compared with Baseline

Trial sites (21)

FacilityCityRegionStatus
University of California, Los Angeles Los Angeles California
University of California, San Francisco San Francisco California
Stanford University Stanford California
Minnesota Urology Bloomington Minnesota
Mayo Clinic Rochester Minnesota
Wake Forest University of Health Sciences Charlotte North Carolina
Duke University Durham North Carolina
Cleveland Clinic Foundation Cleveland Ohio
Vanderbilt University Medical Center Nashville Tennessee
Urology Clinics of North Texas Dallas Texas
University of Texas, Southwestern Dallas Texas
University of Texas, MD Anderson Houston Texas
Urology of Virginia Virginia Beach Virginia
Centre Hospitalier Universitaire de Lille Lille France
Hospitals Academics De Marseille Conception Marseille France
Centre Hospitalier Universitaire de Nantes Nantes France
Groupe Hospitalier Pitié-Salpêtrière Paris France
Centre Hospitalier Univeritaire de Lyon - Hôpital Lyon Sud Pierre-Bénite France
Centre Hospitalier Universitaire de Rennes Rennes France
Centre Hospitalier Universitaire de Rouen Rouen France
Hopital Foch Suresnes France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06968741 on ClinicalTrials.gov ↗ ← All trials in France